- Conditions
- Cocaine Use Disorder
- Interventions
- Semaglutide, Placebo, cognitive behavioral therapy (CBT).
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 902
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Arthritis, Psoriatic
- Interventions
- Tofacitinib, Methotrexate, Placebo Methotrexate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Interventions
- Rituximab plus immunosuppression, Placebo plus immunosuppression
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 5 Years to 70 Years
- Enrollment
- 757 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more
- Conditions
- Overweight and Obesity, Type2 Diabetes, NAFLD
- Interventions
- DD01, Placebo
- Drug
- Lead sponsor
- Neuraly, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Fort Myers, Florida • Orlando, Florida
- Conditions
- H3 K27M, Glioma
- Interventions
- Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
- Conditions
- Obesity
- Interventions
- Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Covina, California • Walnut Creek, California • New Haven, Connecticut + 7 more
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- ALT-801, Placebo
- Drug · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Montclair, California + 9 more
- Conditions
- Demoralization
- Interventions
- Psilocybin, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 25 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
- Interventions
- DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 4
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Obesity
- Interventions
- Behavioral Treatment, Placebo, Phentermine 15 MG
- Behavioral · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Ashibio Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Laser treatment, Sham treatment
- Device
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- IgA Nephropathy
- Interventions
- Telitacicept 160mg, Telitacicept 240mg, Placebo
- Drug
- Lead sponsor
- RemeGen Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Sacramento, California • San Francisco, California + 3 more
- Conditions
- Type 2 Diabetes, Chronic Kidney Disease
- Interventions
- Placebo, Zenagamtide
- Other · Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 26
- States / cities
- La Jolla, California • Lancaster, California • Lincoln, California + 21 more
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma
- Interventions
- Vitamin D, Rituximab, Placebo
- Dietary Supplement · Biological · Other
- Lead sponsor
- Jonathan Friedberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 7
- States / cities
- Miami, Florida • Atlanta, Georgia • Iowa City, Iowa + 4 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- AVI-4658 (Eteplirsen), Placebo
- Drug · Other
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 7 Years to 13 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Cough, Chronic Disease
- Interventions
- Internet-Behavioral Cough Suppression Therapy, Sham Treatment
- Behavioral
- Lead sponsor
- University of Montana
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Missoula, Montana
- Conditions
- Obesity, Knee Osteoarthritis (OA)
- Interventions
- NNC0487-0111, Placebo (matched to NNC0487-0111 )
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Walnut Creek, California • Hamden, Connecticut + 16 more
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- epoetin alfa, placebo
- Biological · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine Hydrochloride XR, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 8 Years to 15 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pruritis
- Interventions
- 50,000 Units Ergocalciferol, Placebo
- Drug
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Bethpage, New York • Mineola, New York
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- NS-065/NCNP-01, Placebo
- Drug
- Lead sponsor
- NS Pharma, Inc.
- Industry
- Eligibility
- 4 Years to 9 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Sacramento, California • Gainesville, Florida • Chicago, Illinois + 3 more